Overview

PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
Phase:
PHASE2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Exegi Pharma, LLC
National Cancer Institute (NCI)
Treatments:
Probiotics